Cost-Effectiveness Analysis of Abiraterone Acetate as Second Line Treatment for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Treatment in Japan
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.532
https://www.valueinhealthjournal.com/article/S1098-3015(13)02437-6/fulltext
Title :
Cost-Effectiveness Analysis of Abiraterone Acetate as Second Line Treatment for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Treatment in Japan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02437-6&doi=10.1016/j.jval.2013.08.532
First page :
A415
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
510